查看犬血管肉瘤化疗管理 – 更新的源代码

== Conclusion ==

在过去的几年中，几种抗癌药物因其对许多恶性肿瘤的疗效而被评估。造成这种趋势的主要原因主要是由于基于蒽环类药物的化疗方案无法对抗血管肉瘤等恶性肿瘤。恶性肿瘤的治疗应基于多模式治疗，该疗法结合了手术切除、化疗、放疗和免疫疗法等不同技术。与单独进行化疗相比，联合疗法是治疗犬血管肉瘤的更好选择。进一步的体内研究对于确定可以有效管理犬血管肉瘤的新药物是必要的。最近的研究为开发有效的化疗药物带来了希望，因为发现几种新的化疗药物对几种血管肉瘤细胞系有效

During the past few years several anti-cancer agents are been evaluated for its efficacy against many malignant tumors. The main reason for such a trend is mostly due to the inability of anthracycline-based chemotherapeutic regimens against malignant tumors like hemangiosarcoma. Management of malignant tumors should be based on multimodal therapy that combines different techniques like surgical excision, chemotherapy, radiation therapy, and immunotherapy. Rather than going for chemotherapy alone combination therapy can be a better option in managing canine hemangiosarcoma. Further in-vivo studies are necessary for identifying newer agents that can effectively manage canine hemangiosarcoma. Recent studies give a hope for the development of effective chemotherapeutic agent since several new chemotherapeutic agents were found to be effective against several hemangiosarcoma cell line

<br>